Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: IGFBP6

Gene summary for IGFBP6

Gene summary.

Gene information	Species	Human
	Gene symbol	IGFBP6
	Gene ID	3489
	Gene name	insulin like growth factor binding protein 6
	Gene Alias	IBP6
	Cytomap	12q13.13
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	P24592

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
3489	IGFBP6	Tumor	Human	Cervix	CC	1.57e-29	7.28e-01	0.1241
3489	IGFBP6	sample3	Human	Cervix	CC	2.28e-26	6.42e-01	0.1387
3489	IGFBP6	T3	Human	Cervix	CC	2.15e-30	6.44e-01	0.1389
3489	IGFBP6	AEH-subject1	Human	Endometrium	AEH	1.22e-28	-6.54e-01	-0.3059
3489	IGFBP6	AEH-subject2	Human	Endometrium	AEH	6.31e-23	-6.51e-01	-0.2525
3489	IGFBP6	AEH-subject3	Human	Endometrium	AEH	1.17e-31	-6.80e-01	-0.2576
3489	IGFBP6	AEH-subject4	Human	Endometrium	AEH	1.08e-16	-6.40e-01	-0.2657
3489	IGFBP6	AEH-subject5	Human	Endometrium	AEH	4.32e-36	-6.92e-01	-0.2953
3489	IGFBP6	EEC-subject1	Human	Endometrium	EEC	2.00e-39	-6.96e-01	-0.2682
3489	IGFBP6	EEC-subject2	Human	Endometrium	EEC	4.59e-39	-7.11e-01	-0.2607
3489	IGFBP6	EEC-subject3	Human	Endometrium	EEC	8.95e-36	-6.66e-01	-0.2525
3489	IGFBP6	EEC-subject4	Human	Endometrium	EEC	2.12e-28	-6.61e-01	-0.2571
3489	IGFBP6	EEC-subject5	Human	Endometrium	EEC	1.38e-33	-6.68e-01	-0.249
3489	IGFBP6	GSM5276934	Human	Endometrium	EEC	8.35e-27	6.16e-01	-0.0913
3489	IGFBP6	GSM5276935	Human	Endometrium	EEC	1.17e-37	-6.95e-01	-0.123
3489	IGFBP6	GSM6177620_NYU_UCEC1_lib1_lib1	Human	Endometrium	EEC	1.03e-28	-7.15e-01	-0.1869
3489	IGFBP6	GSM6177620_NYU_UCEC1_lib2_lib2	Human	Endometrium	EEC	1.19e-25	-7.15e-01	-0.1875
3489	IGFBP6	GSM6177620_NYU_UCEC1_lib3_lib3	Human	Endometrium	EEC	5.88e-25	-6.93e-01	-0.1883
3489	IGFBP6	GSM6177621_NYU_UCEC2_lib1_lib1	Human	Endometrium	EEC	3.75e-43	-7.04e-01	-0.1934
3489	IGFBP6	GSM6177622_NYU_UCEC3_lib1_lib1	Human	Endometrium	EEC	5.43e-41	-7.06e-01	-0.1917

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00160557	Cervix	CC	Wnt signaling pathway	98/2311	444/18723	4.82e-09	4.65e-07	98
GO:01987387	Cervix	CC	cell-cell signaling by wnt	98/2311	446/18723	6.16e-09	5.58e-07	98
GO:00301117	Cervix	CC	regulation of Wnt signaling pathway	76/2311	328/18723	3.05e-08	2.08e-06	76
GO:00310988	Cervix	CC	stress-activated protein kinase signaling cascade	58/2311	247/18723	8.02e-07	2.89e-05	58
GO:00608287	Cervix	CC	regulation of canonical Wnt signaling pathway	58/2311	253/18723	1.83e-06	5.89e-05	58
GO:00600707	Cervix	CC	canonical Wnt signaling pathway	66/2311	303/18723	2.47e-06	7.35e-05	66
GO:00514038	Cervix	CC	stress-activated MAPK cascade	55/2311	239/18723	2.96e-06	8.31e-05	55
GO:00703027	Cervix	CC	regulation of stress-activated protein kinase signaling cascade	46/2311	195/18723	9.35e-06	2.11e-04	46
GO:00434104	Cervix	CC	positive regulation of MAPK cascade	90/2311	480/18723	2.92e-05	4.83e-04	90
GO:00328727	Cervix	CC	regulation of stress-activated MAPK cascade	44/2311	192/18723	3.09e-05	5.10e-04	44
GO:00301784	Cervix	CC	negative regulation of Wnt signaling pathway	35/2311	170/18723	1.52e-03	1.17e-02	35
GO:00900901	Cervix	CC	negative regulation of canonical Wnt signaling pathway	29/2311	137/18723	2.40e-03	1.70e-02	29
GO:00703043	Cervix	CC	positive regulation of stress-activated protein kinase signaling cascade	27/2311	128/18723	3.49e-03	2.26e-02	27
GO:00301118	Endometrium	AEH	regulation of Wnt signaling pathway	71/2100	328/18723	3.31e-08	1.87e-06	71
GO:00160558	Endometrium	AEH	Wnt signaling pathway	85/2100	444/18723	4.99e-07	1.97e-05	85
GO:01987388	Endometrium	AEH	cell-cell signaling by wnt	85/2100	446/18723	6.07e-07	2.29e-05	85
GO:00608288	Endometrium	AEH	regulation of canonical Wnt signaling pathway	54/2100	253/18723	2.22e-06	6.56e-05	54
GO:00514039	Endometrium	AEH	stress-activated MAPK cascade	50/2100	239/18723	9.33e-06	2.18e-04	50
GO:00310989	Endometrium	AEH	stress-activated protein kinase signaling cascade	51/2100	247/18723	1.12e-05	2.52e-04	51
GO:00328728	Endometrium	AEH	regulation of stress-activated MAPK cascade	42/2100	192/18723	1.53e-05	3.23e-04	42

Page: 1 2 3 4 5 6 7 8 9 10

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

IGFBP6

SNV

Missense_Mutation

c.364C>A

p.Pro122Thr

p.P122T

P24592

protein_coding

tolerated(0.1)

benign(0.255)

TCGA-E2-A1II-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

IGFBP6

insertion

Nonsense_Mutation

novel

c.582_583insGGACTGAGGGCAGGCTAGGGCGTAGGTTAGGGGAGAGGGGAGAAAGAG

p.Gly194_Phe195insGlyLeuArgAlaGlyTerGlyValGlyTerGlyArgGlyGluLysGlu

p.G194_F195insGLRAG*GVG*GRGEKE

P24592

protein_coding

TCGA-AR-A0TY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Paclitaxel

IGFBP6

SNV

Missense_Mutation

c.614A>G

p.Gln205Arg

p.Q205R

P24592

protein_coding

deleterious(0.04)

possibly_damaging(0.478)

TCGA-AZ-6598-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

IGFBP6

SNV

Missense_Mutation

c.245N>A

p.Leu82Gln

p.L82Q

P24592

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-CM-4743-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Chemotherapy

capecitabine

IGFBP6

SNV

Missense_Mutation

novel

c.656N>A

p.Gly219Asp

p.G219D

P24592

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AJ-A3BH-01

Endometrium

uterine corpus endometrioid carcinoma

Female

Unknown

I/II

Unknown

IGFBP6

SNV

Missense_Mutation

rs771934053

c.425G>A

p.Gly142Asp

p.G142D

P24592

protein_coding

deleterious(0)

possibly_damaging(0.82)

TCGA-AX-A06F-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

IGFBP6

SNV

Missense_Mutation

rs375017830

c.458N>T

p.Ala153Val

p.A153V

P24592

protein_coding

tolerated(0.14)

benign(0.15)

TCGA-B5-A11E-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

IGFBP6

SNV

Missense_Mutation

novel

c.549N>C

p.Gln183His

p.Q183H

P24592

protein_coding

tolerated(0.75)

benign(0.001)

TCGA-B5-A1MR-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

III/IV

Unknown

IGFBP6

SNV

Missense_Mutation

novel

c.353A>C

p.Lys118Thr

p.K118T

P24592

protein_coding

tolerated(0.21)

possibly_damaging(0.879)

TCGA-B5-A1MX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Hormone Therapy

megace

IGFBP6

SNV

Missense_Mutation

rs201732293

c.491G>A

p.Arg164His

p.R164H

P24592

protein_coding

deleterious(0)

probably_damaging(0.989)

TCGA-B5-A1MX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Hormone Therapy

megace

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
3489	IGFBP6	DRUGGABLE GENOME		ANTISERUM		8940357

Page: 1